Nektar Therapeutics (NASDAQ: NKTR) stock closed at $19.91 on 9/10/19 after a major increase of 11.5%. Moreover, unusually high trading volume at 167% of normal accompanied the advance. The stock has risen 13.3% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
NKTR is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
Nektar Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Nektar Therapeutics has a poor Appreciation Score of 28 and a very low Power Rating of 15, with the Lowest Value Trend Rating the result.
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.